Most patients diagnosed with advanced non-squamous NSCLC with a confirmed biomarker for EGFR, ALK or ROS1 in Norway from 2015 to 2022 received systemic treatment within the first three months since diagnosis (75%, 88%, and 58%, respectively). This evidence concerns the gene ALK and non-small cell lung carcinoma.